Table 3.
Number | Pretreatment PI | Pretreatment NNRTI | Pretreatment NRTI | Endpoint PI | Endpoint NNRTI | Endpoint NRTI |
---|---|---|---|---|---|---|
Maintained on LPV/r-based regimen throughout study period | ||||||
1 | M184V | |||||
2 | K103N | K103N | M184V | |||
3 | M184V | |||||
4 | M184V | |||||
5 | K70E | |||||
6 | ||||||
7 | ||||||
8 | (protease did not amplify) | |||||
Received RTV-based regimen during study period | ||||||
9 | K103N, Y188C | I54V, V82A | M184V | |||
10 | Y181C | K219E | V82A, L90M | M184V | ||
11 | Y181C | V82A | M184I | |||
12 | V82A | M184V | ||||
13 | V82A | M184V | ||||
14 | V82A | M184V | ||||
15 | Y181C | L10F, M46I, I54V, V82A | M184V | |||
16 | Y181C | K219E | L10F, M46I, I54V, V82A | M184V | ||
17 | V179D | M46I, F53L, I54V, V82A | D67N, M184V | |||
18 | M46I, I54V, V82A | A62V, M184V | ||||
19 | Y181C | L33F, I54V, V82A | M184V | |||
20 | L10R, I54V, V82A | A62V, M184V | ||||
21 | L10I | L10I, V82A | M184V | |||
22 | L10F, I54V, Q58E, V82A | D67N, M184V | ||||
23 | E138A | I54V | E138A | M184V | ||
24 | L24I, I54V | E138A | M184V | |||
25 | L10V | M184V | ||||
26 | A71T | A71T | ||||
27 | Y181C | |||||
28 | G190A | G190A | ||||
29 | Y181C | M184V | ||||
30 | M184V | |||||
31 | M184V | |||||
32 | M184V | |||||
33 | M184V | |||||
34 | (protease did not amplify) | M184V | ||||
35 | M184V | |||||
36 | M184V | |||||
37 | ||||||
38 | ||||||
39 | ||||||
40 | ||||||
41 |
Gray shading, data not available; italics, major mutations maintained from baseline; bold, major mutations defined by 2009 IAS-USA list.